Table 5. Association between differential exposures (by serology and DNA) and disease outcome of CIN3/cancer, adjusted by age.
| HPV | Serology | DNA | Total na | CIN3/cancer n (%) | CIN3/cancer positive for another oncogenic type | OR (95% CI) |
|---|---|---|---|---|---|---|
| 16 | + | + | 144 | 21 (14.6) | 4 | 34.7 (19.7–61.0) |
| − | + | 179 | 30 (16.8) | 6 | 39.9 (24.1–66.2) | |
| + | − | 1333 | 15 (1.1) | 11 | 2.0 (1.1–3.7) | |
| − | − | 7456 | 41 (0.5) | 32 | 1.0 | |
| 18 | + | + | 41 | 5 (12.2) | 3 | 16.6 (6.3–43.9) |
| − | + | 80 | 8 (10.0) | 3 | 13.6 (6.3–29.6) | |
| + | − | 1436 | 25 (1.7) | 21 | 1.9 (1.2–3.0) | |
| − | − | 7545 | 68 (0.9) | 59 | 1.0 | |
| 31 | + | + | 63 | 7 (11.1) | 3 | 14.1 (6.2–32.2) |
| − | + | 61 | 3 (4.9) | 2 | 5.7 (1.7–18.7) | |
| + | − | 1502 | 25 (1.7) | 21 | 1.7 (1.1–2.7) | |
| − | − | 7479 | 72 (1.0) | 63 | 1.0 |
a
Total n=9112; HPV-18 and HPV-31 exposure groups do not add up to 9112 due to missing data.